Anika Therapeutics (ANIK) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $19.1 million.
- Anika Therapeutics' Total Current Liabilities fell 2512.06% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year decrease of 2512.06%. This contributed to the annual value of $23.3 million for FY2024, which is 2496.22% down from last year.
- As of Q3 2025, Anika Therapeutics' Total Current Liabilities stood at $19.1 million, which was down 2512.06% from $16.1 million recorded in Q2 2025.
- Anika Therapeutics' Total Current Liabilities' 5-year high stood at $47.0 million during Q1 2021, with a 5-year trough of $16.1 million in Q2 2025.
- For the 5-year period, Anika Therapeutics' Total Current Liabilities averaged around $27.6 million, with its median value being $27.9 million (2022).
- As far as peak fluctuations go, Anika Therapeutics' Total Current Liabilities surged by 7936.84% in 2021, and later plummeted by 4253.72% in 2022.
- Anika Therapeutics' Total Current Liabilities (Quarter) stood at $29.8 million in 2021, then dropped by 6.31% to $27.9 million in 2022, then grew by 11.27% to $31.1 million in 2023, then dropped by 24.96% to $23.3 million in 2024, then fell by 18.09% to $19.1 million in 2025.
- Its Total Current Liabilities stands at $19.1 million for Q3 2025, versus $16.1 million for Q2 2025 and $17.9 million for Q1 2025.